Anavex Life Sciences Corp (AVXL) Com Stk USD0.001

Sell:$8.01Buy:$8.02$0.62 (7.23%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$8.01
Buy:$8.02
Change:$0.62 (7.23%)
Market closed | Prices delayed by at least 15 minutes
Sell:$8.01
Buy:$8.02
Change:$0.62 (7.23%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.

Key people

Christopher U. Missling
Chairman of the Board, President, Chief Executive Officer, Company Secretary
Sandra Boenisch
Principal Financial Officer, Treasurer
Peter Donhauser
Independent Director
Jiong Ma
Independent Director
Athanasios Skarpelos
Independent Director
Steffen Thomas
Independent Director
Claus van der Velden
Independent Director
Click to see more

Key facts

  • EPIC
    AVXL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0327973006
  • Market cap
    $729.85m
  • Employees
    42
  • Shares in issue
    85.06m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.